收入和销售 - 公司2023年全球收入为3.224亿美元，其中99%来自ICL销售[110] - ICL销售在2023年增长了18%，达到3.194亿美元，占销售总额的99.1%[113] - 2023年亚太地区ICL销售增长21%，主要市场如中国增长25%，印度增长14%[113] - 2023年美洲地区ICL销售增长11%，其中美国市场增长14%[113] - 2023年其他产品销售下降80%，主要由于停止销售白内障IOL产品[113] - 2023年总运营费用占销售额的69.6%，其中销售和营销费用占33.4%[112] - 2023年销售和营销费用为107,834千美元，较2022年增长21.4%，主要由于增加的广告和促销活动、工资相关的薪资税费用、销售佣金费用和旅行费用[119] - 2023年研发费用为44,401千美元，较2022年增长23.4%，主要由于增加的工资相关和薪资税费用以及与美国后批准临床试验相关的临床费用[121] - 2023年其他收入（费用）净额为5,599千美元，主要由于2023年较高的利息收入[123] - 2023年所得税准备为12,349千美元，有效税率36.6%[125] - 中国分销商占公司2023财年总销售额的58%，销售以美元计价[144] 财务状况 - 2023年公司毛利率为78.4%，较2022年的78.5%略有下降[115] - 2023年现金及现金等价物为183,038千美元，较2022年增加96,558千美元[129] - 2023年投资活动提供的现金为74,347千美元，主要来自出售或到期投资的收益[130] - 2023年融资活动提供的现金为7,415千美元，主要来自股票期权的行使[130] - 2023年应收账款净额为94,700千美元，较2022年增加，应收账款周转天数（DSO）为113天[130] - 2023年存货净额为35,100千美元，较2022年增加，存货周转天数（DOH）为142天[130] - 2023年合同义务总额为69,438千美元，其中一年内到期的为23,106千美元[130] 战略和计划 - 2024年公司计划增加与领先屈光外科医生和实践的战略合作，投资新产品创新，包括新一代镜片技术[111] - 公司计划在2024年继续推动ICL手术的认知度，扩大产品在全球市场的可用性[111] - 公司正在评估收购新产品线、技术和公司的机会[111] 风险和挑战 - 公司国际业务占总销售额的95%，主要货币风险包括日元、欧元和瑞士法郎[143] - 公司未采取对冲措施来抵消外汇变动的影响[139][142][143] - 公司认为通胀在过去三年未对净销售额和持续经营收入产生显著影响[140] - 公司面临外汇汇率波动风险，尤其是美元走强可能影响以美元计的合并销售额和毛利润[144] - 公司未采用会计准则中尚未实施的最新会计准则[141] - 公司养老金计划的负债和年度收入或支出基于多种精算假设，包括折现率、预期服务年限、薪资增长和预期长期资产回报率[138] - 公司面临市场风险，包括利率和外汇汇率波动，但未使用对冲工具[142] - 公司同意延长中国分销商的付款期限，以应对汇率波动[144] 运营管理 - 公司定期审查库存，主要基于产品有效期、未来需求预测和未来12个月的产量需求[137]

STAAR Surgical Company (NASDAQ:STAA) Q4 2023 Earnings Conference Call February 26, 2024 4:15 PM ET Company Participants Brian Moore - Vice President-Investor Relations & Corporate Development Tom Frinzi - President & Chief Executive Officer Patrick Williams - Chief Financial Officer. Conference Call Participants Patrick Wood - Morgan Stanley John Young - Canaccord Margaret Andrew - William Blair George Sellers - Stephens Inc. Ryan Zimmerman - BTIG Anthony Petrone - Mizuho Group Matthew O'Brien - Piper Sandl ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 29, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 0-11634 STAAR Surgical Company (Exact Name of Registrant as Specified in its Charter) Delaware 95-3797439 (State or Other Jurisdiction of (I.R.S. Employer Incor ...

STAAR Surgical Company (NASDAQ:STAA) Q3 2023 Earnings Conference Call November 1, 2023 4:30 PM ET Company Participants Brian Moore - Vice President-Investor Relations & Corporate Development Tom Frinzi - President & Chief Executive Officer Patrick Williams - Chief Financial Officer. Conference Call Participants Anthony Petrone - Mizuho Xuyang Li - Jefferies John Young - Canaccord George Sellers - Stephens Margaret Kaczor Andrew - William Blair Steve Lichtman - Oppenheimer Operator Good day ladies and gentle ...

STAAR Surgical Company (NASDAQ:STAA) Q2 2023 Earnings Conference Call August 2, 2023 4:30 PM ET Company Participants Brian Moore - Investor Relations Tom Frinzi - President and Chief Executive Officer Patrick Williams - Chief Financial Officer Conference Call Participants Anthony Petrone - Mizuho Group Margaret Kaczor - William Blair Young Li - Jefferies Samuel Durno - BTIG Harrison Parsons - Stephens Inc. Tom Stephan - Stifel David Saxon - Needham Jim Sidoti - Sidoti & Company Steve Lichtman - Oppenheimer ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 0-11634 STAAR Surgical Company (Exact Name of Registrant as Specified in its Charter) Delaware 95-3797439 (State or Other Jurisdiction of (I.R.S. Employer Incorporat ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 0-11634 STAAR Surgical Company (Exact Name of Registrant as Specified in its Charter) Delaware 95-3797439 (State or Other Jurisdiction of (I.R.S. Employer Incorpora ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 30, 2022 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-11634 STAAR SURGICAL COMPANY (Exact name of registrant as specified in its charter) Delaware 95-3797439 (State or other jurisdiction o ...